2022
Cancer Drug Dosing in Chronic Kidney Disease and Dialysis
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Advances In Kidney Disease And Health 2022, 29: 208-216.e1. PMID: 35817528, DOI: 10.1053/j.ackd.2021.12.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseKidney functionEnd-stage kidney diseasePatient's kidney functionRenal replacement therapyCurrent dosing strategiesClassic chemotherapeutic drugsReplacement therapyDosing strategiesHigh prevalenceDrug dosingKidney metabolismAntineoplastic agentsPharmacokinetic propertiesChemotherapeutic drugsDiseaseSpecific agentsPatientsDosingTherapyDrugsAgentsImmunotherapyMalignancy
2015
Nephrotoxicity of Chemotherapy Agents
Valika A, Shirali A. Nephrotoxicity of Chemotherapy Agents. 2015, 65-91. DOI: 10.1007/978-1-4939-2659-6_4.Peer-Reviewed Original ResearchChemotherapy agentsAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsChemotherapy-induced nephrotoxicityIntrinsic renal injurySite-specific injuryAcute tubular necrosisGrowth factor agentsGlomerular endothelial damageAdverse drug effectsDistinct clinical syndromeFactor agentsCrystal nephropathyHemodynamic statusPatient characteristicsRenal injuryTubular necrosisEndothelial damageKidney functionClinical syndromeVascular injuryKidney microenvironmentMalignant diseaseGlomerular diseaseDrug effects